Cargando…
Ubiquitination and Degradation of Ribonucleotide Reductase M1 by the Polycomb Group Proteins RNF2 and Bmi1 and Cellular Response to Gemcitabine
Ribonucleotide reductase M1 (RRM1) is required for mammalian deoxyribonucleotide (dNTP) metabolism. It is the primary target of the antimetabolite drug gemcitabine, which is among the most efficacious and most widely used cancer therapeutics. Gemcitabine directly binds to RRM1 and irreversibly inact...
Autores principales: | Zhang, Yingtao, Li, Xin, Chen, Zhengming, Bepler, Gerold |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948819/ https://www.ncbi.nlm.nih.gov/pubmed/24614341 http://dx.doi.org/10.1371/journal.pone.0091186 |
Ejemplares similares
-
Modulation of the Ribonucleotide Reductase-Antimetabolite Drug Interaction in Cancer Cell Lines
por: Zhou, Jun, et al.
Publicado: (2010) -
A Kinome Screen Identifies Checkpoint Kinase 1 (CHK1) as a Sensitizer for RRM1-Dependent Gemcitabine Efficacy
por: Zhou, Jun, et al.
Publicado: (2013) -
Ribonucleotide reductase is not limiting for mitochondrial DNA copy number in mice
por: Ylikallio, Emil, et al.
Publicado: (2010) -
Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine
por: Goss, Kelli L, et al.
Publicado: (2017) -
Ubiquitin ligase RNF125 targets PD-L1 for ubiquitination and degradation
por: Wei, Meng, et al.
Publicado: (2022)